Iatrogenic Cushing's Syndrome Post Intralesional Triamcinolone Acetonide in Oral Submucous Fibrosis: 2 Case Reports

This document describes two cases where patients developed iatrogenic Cushing's syndrome after receiving intralesional injections of Triamcinolone Acetonide (TAC) to treat Oral Submucous Fibrosis (OSF). A 44-year-old female and a 40-year-old male, both with a history of betel quid chewing, showed improvement in mouth opening after TAC treatment but developed symptoms of Cushing's syndrome, such as facial rounding and swelling in the lower extremities. Elevated cortisol levels were observed in both cases. Upon discontinuing TAC, the symptoms of Cushing's syndrome resolved within a year, and cortisol levels returned to normal. The report emphasizes the need for careful monitoring of patients receiving TAC for OSF due to the potential for serious side effects.